These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 32721416)
1. Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fcγ receptors. Shock A; Humphreys D; Nimmerjahn F J Allergy Clin Immunol; 2020 Sep; 146(3):492-500. PubMed ID: 32721416 [TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Schwab I; Nimmerjahn F Nat Rev Immunol; 2013 Mar; 13(3):176-89. PubMed ID: 23411799 [TBL] [Abstract][Full Text] [Related]
3. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention. Patel DD; Bussel JB J Allergy Clin Immunol; 2020 Sep; 146(3):467-478. PubMed ID: 32896307 [TBL] [Abstract][Full Text] [Related]
4. New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases. Norris PAA; Kaur G; Lazarus AH Curr Opin Hematol; 2020 Nov; 27(6):392-398. PubMed ID: 32868670 [TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases. Ruiz de Souza V; Kaveri SV; Kazatchkine MD Clin Exp Rheumatol; 1993; 11 Suppl 9():S33-6. PubMed ID: 8354005 [TBL] [Abstract][Full Text] [Related]
6. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases. Hurez V; Kaveri SV; Kazatchkine MD J Autoimmun; 1993 Dec; 6(6):675-81. PubMed ID: 8155249 [TBL] [Abstract][Full Text] [Related]
7. 7th International Immunoglobulin Conference: Mechanisms of action. Basta M; Branch DR Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):111. PubMed ID: 25546783 [TBL] [Abstract][Full Text] [Related]
8. Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin. Ahmed AR; Kaveri S Front Immunol; 2018; 9():1189. PubMed ID: 30072982 [TBL] [Abstract][Full Text] [Related]
9. Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation. Brückner C; Lehmann C; Dudziak D; Nimmerjahn F Int Immunol; 2017 Dec; 29(11):499-509. PubMed ID: 29300958 [TBL] [Abstract][Full Text] [Related]
10. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. Li N; Zhao M; Hilario-Vargas J; Prisayanh P; Warren S; Diaz LA; Roopenian DC; Liu Z J Clin Invest; 2005 Dec; 115(12):3440-50. PubMed ID: 16284651 [TBL] [Abstract][Full Text] [Related]
11. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. Peter HH; Ochs HD; Cunningham-Rundles C; Vinh DC; Kiessling P; Greve B; Jolles S J Allergy Clin Immunol; 2020 Sep; 146(3):479-491.e5. PubMed ID: 32896308 [TBL] [Abstract][Full Text] [Related]
12. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Galeotti C; Kaveri SV; Bayry J Int Immunol; 2017 Dec; 29(11):491-498. PubMed ID: 28666326 [TBL] [Abstract][Full Text] [Related]
13. Modulation of autoimmune responses by intravenous immunoglobulin (IVIg). Kaveri S; Prasad N; Vassilev T; Hurez V; Pashov A; Lacroix-Desmazes S; Kazatchkine M Mult Scler; 1997 Apr; 3(2):121-8. PubMed ID: 9291165 [TBL] [Abstract][Full Text] [Related]